SCHEMBL6861924

SCHEMBL6861924

CCOC(=O)c1ccc2c(c1)CCC(C(=O)O)O2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 5/20 0.57
CYP4A11 Q02928 5/20 0.57
PPARG P37231 2/20 0.45
PPARA Q07869 1/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
ALDH1A1 P00352 3/20 0.43
ALOX15 P16050 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
MASP2 O00187 1/20 0.43
MEN1 O00255 1/20 0.43
GAPDH P04406 1/20 0.43
POLB P06746 1/20 0.43
HSPA1A P0DMV8 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6863568 0.81 CYP4F2 (0.47) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL18144926 0.81 TDP1 (0.55) CYP4F2CYP4A11PPARGPPARAALDH1A1
Hydrochloric Acid SCHEMBL6863563 0.81 CYP4F2 (0.46) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL6854482 0.81 CYP4F2 (0.46) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL14457112 0.80 CYP4F2 (0.60) CYP4F2CYP4A11PPARGPPARACYSLTR2
SCHEMBL6861869 0.79 CYP4F2 (0.65) CYP4F2CYP4A11PPARGPPARA
SCHEMBL11489858 0.79 MAPT (0.49) CA12CA1CA2CA7CA9
SCHEMBL433940 0.78 CYP4F2 (0.50) CYP4F2CYP4A11PPARGPPARAHPGD
SCHEMBL16742283 0.78 POLB (0.57) CYP4F2CYP4A11CA12CA1CA2
SCHEMBL16742240 0.78 MAPT (0.47) CYP4F2CYP4A11CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6797714-B2 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION BAYER PHARMACEUTICALS CORPORATION 2004-09-28 US disclosed
US-20030013705-A1 Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists BAYER PHARMACEUTICALS CORPORATION 2003-01-16 US disclosed
US-6469031-B1 USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS HYPER-TRIGLYCERIDAEMIA, HYPERCHOLESTEROLAEMIA AND IN LOWERING HIGH DENSITY LIPOPROTEIN LEVELS AS WELL AS IN THE TREATMENT OF ATHEROSCLEROTIC, CARDIOVASCULAR AND DIABETIC CONDITIONS BAYER CORPORATION 2002-10-22 US disclosed
EP-1040106-B1 CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS BAYER AG (US) 2002-08-28 EP disclosed
CN-1284952-A Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists BAYER AG (US) 2001-02-21 CN disclosed
EP-1040106-A1 CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS Bayer Corporation (US) 2000-10-04 EP disclosed
WO-1999032476-A1 CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS BAYER CORPORATION (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013705-A1 Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists ADRB3, ADRB1, ADRB2 CYP4F2 1328/4885CYP4A11 301/4885PPARG 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.